期刊文献+

新型抗肿瘤药PI-88及其类似物 被引量:6

Novel anticancer agents:PI-88 and its mimetics
下载PDF
导出
摘要 硫酸乙酰肝素类似物PI-88是一种有前景的肿瘤生长及转移抑制剂,可作为肝癌切除手术后的辅助治疗,通过抑制血管生长而产生抗肿瘤作用。同时它也是一种强效的乙酰肝素酶抑制剂,乙酰肝素酶是一种在肿瘤转移以及血管生长过程中起关键作用的酶。已经合成一系列PI-88类似物,这些类似物都可抑制乙酰肝素酶,与成纤维细胞生长因子(FGF)-1,FGF-2,血管内皮生长因子的亲和力和PI-88类似。与PI-88相比,有些新化合物显示出更强的抑制生长因子诱导的内皮细胞增殖及内皮细胞管道生成的作用,体内试验也证实有明显的抑制血管生成的作用。此外,部分新化合物药代动力学性质也得到改善。PI-88及其类似物作为一类有效抑制血管生长的抗肿瘤药物的研究正在进行中。 The heparan sulfate (HS) mimetic PI-88 is a promising inhibitor of tumor growth and metastasis as an adjuvant therapy for postreseetion hepatoeellular carcinoma. Its anti-neoplastic effect is mediated through the inhibition of tumor angiogenesis. It is also a potent inhibitor of heparanase, an enzyme that plays a key role in both tumor metastasis and angiogenesis. A series of PI-88 analogues have been synthesized, which can inhibit heparanase and bind to the angiogenie fibroblast growth factor 1 (FGF-1), FGF- 2, and vascular endothelial growth factor with similar affinity to PI-88. However, compared with PI-88, some of the newly designed compounds are more potent inhibitos of growth factor-induced endothelial cell proliferation and of endothelial tube formation on matrigel. Representative compounds were also tested for antiangiogenie activity in vivo and were found to reduce significantly blood vessel formation. Moreover, the pharmacokinetic profile of several analogues was also improved. The current data support the development of PI-88 mimetics as potent antiangiogenie antieancer agents.
机构地区 中山大学药学院
出处 《国际药学研究杂志》 CAS 2008年第6期411-414,共4页 Journal of International Pharmaceutical Research
关键词 PI-88 硫酸乙酰肝素类似物 乙酰肝素酶抑制剂 血管生成抑制剂 抗肿瘤药 PI-88 heparan sulfate mimetics heparanase inhibitors angiogenesis inhibitors antineoplastic agents
  • 相关文献

参考文献25

  • 1[1]Carmeliet P,Jain RK.Angiogenesis in cancer and other diseases[J].Nature,2000,407(14):249-257. 被引量:1
  • 2[2]Bergers G.Benjamin LE.Tumorigenesis and the angiogenic switch[J].Nat Rev Cancer,2003,3(6):401-410. 被引量:1
  • 3[3]Herbst RS.Therapeutic options to target angiogenesis in human malignancies[J].Exp Opin Emerg Drugs,2006,11(4):635-650. 被引量:1
  • 4[4]Sasisekharan R.Shriver Z,Venkataraman G,et al.Roles of heparan-sulphate glycosaminoglycans in cancer[J].Nat Rev Cancer,2002,2(7):521-528. 被引量:1
  • 5[5]Wegrowski Y,Maquart FX.Involvement of stromal proteoglycans in tumour progression[J].Crit Rev Oncol Hematol,2004,49(3):259-268. 被引量:1
  • 6[6]Lever R,Page CP.Novel drug development opportunities for heparin[J].Nat Rev Drug Discov,2002,1(2):140-148. 被引量:1
  • 7[7]Presta M,Leali D,Stabile H,et al.Heparin derivatives as angiogenesis inhibitors[J].Curr Pharm Des,2003,9(7):553-566. 被引量:1
  • 8[8]Parish CR,Freeman C,Brown KJ,et al.Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity[J].Cancer Res,1999,59(14):3433-3441. 被引量:1
  • 9[9]Cochran S,Li C,Fairweather JK,et al.Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance[J].Med Chem,2003,46(21):4601-4608. 被引量:1
  • 10[10]Khachigian LM,Parish CR.Phosphomannopentaose sulfate (PI-88):heparan sulfate mimetic with clinical potential in multiple vascular pathologies[J].Cardiovasc Drug Rev,2004,22(1):1-6. 被引量:1

同被引文献107

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部